The Medical College of Wisconsin, Inc.

1. BeiGene, Ltd. $3,613,629 250 payments
2. Genentech, Inc. $2,574,981 271 payments
3. BeOne Medicines Ltd. $2,225,049 36 payments
4. BioMarin Pharmaceutical Inc. $2,191,860 259 payments
5. Roche Products Limited $492,097 30 payments
6. United Therapeutics Corporation $448,893 125 payments
7. ADC Therapeutics America, Inc. $295,419 53 payments
8. Merck Sharp & Dohme Corporation $295,296 3 payments
9. Jazz Pharmaceuticals Inc. $254,059 2 payments
10. F. Hoffmann-La Roche AG $231,981 7 payments

1. A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia $4,431,600 68 payments
2. A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) $691,904 122 payments
3. A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia $630,658 69 payments
4. A Phase III Study to Evaluate the Efficacy and Safety of Fenebrutinib in Adults With Progressive Ms $574,192 30 payments
5. Ph1b 2 TDB Pola Dose Escalation in R R NHL Ph1b Followed By Expansion in R R Dlbcl and R R FL Ph2 $514,779 31 payments
6. Morpheus Pancreatic $492,097 30 payments
7. A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies $417,661 49 payments
8. Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study $415,928 28 payments
9. A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) $333,843 67 payments
10. A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX -351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies $254,059 2 payments

1. Other $21,464 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.